MET and non-small cell lung carcinoma: Preliminary results were presented from the phase I SHIELD trial of elzovantinib, a MET, SRC, and CSF1R inhibitor, in 52 patients with MET dysregulated solid tumors, including 30 patients with MET-altered NSCLC (20 MET-ex14 skipping mutations, 8 MET amplified, 2 other MET mutations) [130].